Study of CM313 in Healthy Subjects
This study is a single center, randomized, open/double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacokinetic characteristics, and immunogenicity of CM313 administered subcutaneously or intravenously at different doses in healthy male subjects.
- EligibilityCriteria: Inclusion Criteria:  Subjects age ≥ 18 years & ≤50 years. Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.  Exclusion Criteria:  With history of malignant tumors; Plan to undergo major surgery during the research period Known to be allergic to monoclonal antibody drugs or other related drugs, food, or CM313 excipients; With any voluntary blood donation or any other form of blood loss exceeding 400 mL; The average daily smoking volume within the first three months of screening is greater than 5 cigarettes; Positive results in baseline alcohol breath test or urine drug abuse screening. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Male - MinimumAge: 18 Years - MaximumAge: 50 Years - StdAgeList: Adult